基本數據
| LEI | 5493000KUTPFGOPAT717 |
| CIK | 1425450 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to OrthoPediatrics Corp.
SEC Filings (Chronological Order)
本頁面提供了一個完整的、按時間順序排列的美國證券交易委員會（SEC）申報文件列表，不包括我們在其他地方提供的所有權申報。
| June 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2026 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission File |
|
| May 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38242 OrthoPedi |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2026 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fi |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2026 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fi |
|
| April 30, 2026 |
OrthoPediatrics Corp. Reports First Quarter 2026 Financial Results and Increases 2026 Financial Guidance First Quarter 2026 Revenue Increased 13% Year-over-Year WARSAW, Ind., April 30, 2026 - OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first qu |
|
| April 30, 2026 |
april2026orthopediatrics 2026 Investor Presentation www.OrthoPediatrics.com 22 0 2 6 / / Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial |
|
| April 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 20, 2026 |
annualreport2025-digital OP - Annual Report 2025 | 1 ANNUAL REPORT I M P R O V I N G T H E L I V E S O F K I D S 2 0 2 5 We are helping children whose lives have been impacted by orthopedic conditions. |
|
| April 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fi |
|
| April 1, 2026 |
Exhibit 10.1 FIRST AMENDMENT THIS FIRST AMENDMENT (this “Agreement”) is entered into as of March 31, 2026 (the “First Amendment Effective Date”), by and among ORTHOPEDIATRICS CORP., a Delaware corporation, ORTHOPEDIATRICS US DISTRIBUTION CORP., a Delaware corporation, VILEX IN TENNESSEE, INC., a Tennessee corporation, ORTHEX, LLC, a Florida limited liability company, TELOS PARTNERS, LLC, a Colorad |
|
| March 4, 2026 |
Subsidiaries of OrthoPediatrics Corp. As of December 31, 2025 Subsidiaries of OrthoPediatrics Corp. As of December 31, 2025 All subsidiaries are 100% owned, except Plagio Prevention, LLC, which is 50% owned, directly or indirectly. Name of Subsidiary Jurisdiction of Formation Domestic Subsidiaries: Orthotic Specialists, Inc. Arizona Pediatrics Specialists - Colorado, LLC Colorado Telos Partners, LLC Colorado MacyOP, LLC Connecticut OrthoPediatrics US Distrib |
|
| March 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K [Mark One] ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38242 ORTHOPEDIATRICS CORP. |
|
| March 4, 2026 |
LIMITED POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS that the undersigned directors and officers of OrthoPediatrics Corp. |
|
| March 4, 2026 |
INSIDER TRADING COMPLIANCE POLICY ORTHOPEDIATRICS CORP. INSIDER TRADING COMPLIANCE POLICY OF ORTHOPEDIATRICS CORP. CONTENTS Page I.SUMMARY 1 II.STATEMENT OF POLICIES PROHIBITING INSIDER TRADING 1 III.EXPLANATION OF INSIDER TRADING 2 IV.STATEMENT OF PROCEDURES PREVENTING INSIDER TRADING 6 V.ADDITIONAL PROHIBITED TRANSACTIONS 9 VI.RULE 10b5-1 TRADING PLANS, SECTION 16 AND RULE 144 10 VII.EXECUTION AND RETURN OF CERTIFICATION OF COMPLIANCE 16 ATTACHMENT A |
|
| March 4, 2026 |
DESCRIPTION OF ORTHOPEDIATRICS CORP. CAPITAL STOCK DESCRIPTION OF ORTHOPEDIATRICS CORP. CAPITAL STOCK The following description summarizes some of the terms of our capital stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws, and the Delaware General Corporation Law, or the DGCL. Because it is only a summary, it does not contain all the information that may be important to you. For a |
|
| February 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| February 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| February 26, 2026 |
orthopediatrics-investor 2026 Investor Presentation www.OrthoPediatrics.com 22 0 2 6 / / Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial |
|
| February 26, 2026 |
OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2025 Financial Results Record full year 2025 revenue of $236.3 million increased 15% compared to prior year Operating Cash flow improvement of $22 million in full year 2025 Generated $10 million of free cash flow in the fourth quarter, the first quarter of positive free cash flow in Company history WARSAW, Ind., February 26, 2026 - OrthoPe |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| January 12, 2026 |
kids4q25preav8 2850 Frontier Drive | Warsaw, IN 46582 Ph: 574.268.6379 | Fax: 574.268.6302 www.orthopediatrics.com OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2025 and Issues 2026 Financial Guidance Achieves all-time high full year 2025 Revenue of $236.1 million representing growth of 15% over prior year Initiates guidance for record Adjusted EBITDA in 2026 Wa |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| January 12, 2026 |
kidsjpmpresentation 2026 Investor Presentation www.OrthoPediatrics.com 22 0 2 6 / / Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial perf |
|
| October 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38242 Ortho |
|
| October 28, 2025 |
kidsoctober2025investorp 2025 Investor Presentation www.OrthoPediatrics.com 22 0 2 5 / / Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial |
|
| October 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2025 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| October 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2025 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| October 28, 2025 |
OrthoPediatrics Corp. Reports Third Quarter 2025 Financial Results Increased Third Quarter 2025 Revenue 12% Year-over-year, and Increased Adjusted EBITDA by 56% year-over-year WARSAW, Ind., October 28, 2025 - OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results |
|
| October 9, 2025 |
kidsprelim3q25v4-finalsa OrthoPediatrics Corp. Announces Preliminary Third Quarter 2025 Revenue and Revised 2025 Guidance Company to host conference call today, October 9th, 2025, to discuss the financial results and updated outlook WARSAW, Ind., October 9, 2025 - OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pedi |
|
| October 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2025 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission F |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fi |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38242 OrthoPedia |
|
| August 5, 2025 |
OrthoPediatrics Corp. Reports Second Quarter 2025 Financial Results and Increases Full Year 2025 Revenue Guidance Second Quarter 2025 Revenue Surpasses $60 million for the First Time in Company History, and Increased Adjusted EBITDA by 58% year-over-year WARSAW, Ind., August 5, 2025 - OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advanc |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fi |
|
| August 5, 2025 |
opsbclinicexpansioniiv4 2850 Frontier Drive | Warsaw, IN 46582 Ph: 574.268.6379 | Fax: 574.268.6302 www.orthopediatrics.com OrthoPediatrics Corp. Announces Continued Expansion of Specialty Bracing Division Into New Territories with Multiple Clinics Warsaw, IN – August 5, 2025 – OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the |
|
| August 5, 2025 |
kidsaug2025investorprese 2025 Investor Presentation www.OrthoPediatrics.com 22 0 2 5 / / Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fi |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fi |
|
| June 25, 2025 |
June 25, 2025 David R. Bailey President and Chief Executive Officer Orthopediatrics Corp 2850 Frontier Drive Warsaw, Indiana 46582 Re: Orthopediatrics Corp Form 10-K for the Fiscal Year Ended December 31, 2024 File No. 001-38242 Dear David R. Bailey: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their |
|
| June 24, 2025 |
seccommentletter2respons 2850 Frontier Drive | Warsaw, IN 46582 Ph: 574.268.6379 | Fax: 574.268.6302 www.orthopediatrics.com June 24, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services Attention: Ms. Christie Wong and Ms. Li Xiao Re: OrthoPediatrics Corp. Form 10-K for the Fiscal Year Ended December 31, 2024 Response Dat |
|
| June 11, 2025 |
June 11, 2025 David R. Bailey President and Chief Executive Officer Orthopediatrics Corp 2850 Frontier Drive Warsaw, Indiana 46582 Re: Orthopediatrics Corp Form 10-K for the Fiscal Year Ended December 31, 2024 Response Dated June 2, 2025 File No. 001-38242 Dear David R. Bailey: We have reviewed your response to our comment letter and have the following comment. Please respond to this letter within |
|
| June 2, 2025 |
seccommentletterresponse 2850 Frontier Drive | Warsaw, IN 46582 Ph: 574.268.6379 | Fax: 574.268.6302 www.orthopediatrics.com June 2, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services Attention: Ms. Christie Wong and Ms. Li Xiao Re: OrthoPediatrics Corp. Form 10-K for the Fiscal Year Ended December 31, 2024 Filed March 5 |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission File |
|
| May 20, 2025 |
May 20, 2025 David R. Bailey President and Chief Executive Officer Orthopediatrics Corp 2850 Frontier Drive Warsaw, Indiana 46582 Re: Orthopediatrics Corp Form 10-K for the Fiscal Year Ended December 31, 2024 File No. 001-38242 Dear David R. Bailey: We have limited our review of your filing to the financial statements and related disclosures and have the following comments. Please respond to this |
|
| May 14, 2025 |
amendmenttomembershipint FIRST AMENDMENT TO MEMBERSHIP INTEREST PURCHASE AGREEMENT This First Amendment to the Membership Interest Purchase Agreement (the “First Amendment”) is made and entered into as of this 9th day of May 2025 (the “Effective Date”) by and among OrthoPediatrics Corp. |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission File |
|
| May 8, 2025 |
OrthoPediatrics Corp. Non-Employee Director Compensation Policy, effective May 6, 202 24709700.v3 ORTHOPEDIATRICS CORP. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Effective as of May 6, 2025) OrthoPediatrics Corp. (the “Company”) believes that granting equity and cash compensation to its directors who are not employees of the Company (“Outside Directors”) represents a powerful tool to attract, retain and reward its Outside Directors and to align the interests of its Outside Directo |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38242 OrthoPedi |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission File |
|
| May 7, 2025 |
OrthoPediatrics Corp. Reports First Quarter 2025 Financial Results and Increases Full Year 2025 Revenue Guidance First Quarter 2025 Revenue Increased 17% Year-over-Year WARSAW, Ind., May 7, 2025 - OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the fir |
|
| May 7, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission File |
|
| May 7, 2025 |
kidsmay2025investorprese 2025 Investor Presentation www.OrthoPediatrics.com 22 0 2 5 / / Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Amendment No. 1) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defi |
|
| April 2, 2025 |
This page is intentionally left blank This page is intentionally left blank a2024annualreportdigital This page is intentionally left blank This page is intentionally left blank |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 6, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fil |
|
| March 6, 2025 |
2025 Investor Presentation www.OrthoPediatrics.com 22 0 2 5 / / Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and conditio |
|
| March 5, 2025 |
DESCRIPTION OF ORTHOPEDIATRICS CORP. CAPITAL STOCK The following description summarizes some of the terms of our capital stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws, and the Delaware General Corporation Law, or the DGCL. Because it is only a summary, it does not contain all the information that may be important to you. For a |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K [Mark One] ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38242 ORTHOPEDIATRICS CORP. |
|
| March 5, 2025 |
Insider Trading Compliance Policy of OrthoPediatrics Corp. i OC\2208306.2 10-15-2020 08:58 INSIDER TRADING COMPLIANCE POLICY OF ORTHOPEDIATRICS CORP. CONTENTS Page I. SUMMARY .........................................................................................................................1 II. STATEMENT OF POLICIES PROHIBITING INSIDER TRADING ...............................1 III. EXPLANATION OF INSIDER TRADING ...................................... |
|
| March 5, 2025 |
Subsidiaries of the registrant Subsidiaries of OrthoPediatrics Corp. As of December 31, 2024 All subsidiaries are 100% owned, except Plagio Prevention, LLC, which is 50% owned, directly or indirectly. Name of Subsidiary Jurisdiction of Formation Domestic Subsidiaries: OrthoPediatrics US Distribution Corp. Delaware Vilex in Tennessee, Inc. Tennessee Orthex, LLC Florida Telos Partners, LLC Colorado MD Orthopaedics, Inc. Iowa MD I |
|
| March 5, 2025 |
LIMITED POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS that the undersigned directors and officers of OrthoPediatrics Corp. |
|
| March 4, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fil |
|
| March 4, 2025 |
OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results Record full year 2024 revenue of $204.7 million increased 38% compared to prior year, and more than doubled fourth quarter 2024 adjusted EBITDA WARSAW, Ind., March 4, 2025 - OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric ort |
|
| January 14, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| January 14, 2025 |
2025 Investor Presentation www.OrthoPediatrics.com 22 0 2 5 / / Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and conditio |
|
| January 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| January 13, 2025 |
OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2024 and Issues 2025 Financial Guidance Achieves all-time high full year 2024 Revenue of $205 million representing growth of 38% Year-Over-Year Initiates guidance for record adjusted EBITDA in 2025 WARSAW, Ind., January 13, 2025 - OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company fo |
|
| November 14, 2024 |
KIDS / OrthoPediatrics Corp. / BROWN CAPITAL MANAGEMENT LLC Passive Investment SC 13G/A 1 fp0090934-8sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 6)* OrthoPediatrics Corp. (Name of Issuer) Class A common stock, $0.00025 par value (Title of Class of Securities) 68752L100 |
|
| November 12, 2024 |
2024 Investor Presentation www.OrthoPediatrics.com 22 0 2 4 / / Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and conditio |
|
| November 12, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| November 8, 2024 |
KIDS / OrthoPediatrics Corp. / BlackRock, Inc. Passive Investment SC 13G 1 us68752l1008110824.txt us68752l1008110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) ORTHOPEDIATRICS CORP - (Name of Issuer) Common Stock - (Title of Class of Securities) 68752L100 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38242 Ortho |
|
| November 7, 2024 |
OrthoPediatrics Corp. Non-Employee Director Compensation Policy, effective August 8, 2024. Exhibit 10.10 ORTHOPEDIATRICS CORP. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Effective as of August 8, 2024) OrthoPediatrics Corp. (the “Company”) believes that granting equity and cash compensation to its directors who are not employees of the Company (“Outside Directors”) represents a powerful tool to attract, retain and reward its Outside Directors and to align the interests of its Outside Di |
|
| November 6, 2024 |
OrthoPediatrics Corp. Reports Third Quarter 2024 Financial Results and Increases Full Year 2024 Revenue Guidance Record Third Quarter 2024 Revenue Increased 37% Year-over-Year WARSAW, Ind., November 6, 2024 - OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| October 22, 2024 |
KIDS / OrthoPediatrics Corp. / BlackRock, Inc. Passive Investment SC 13G 1 us68752l1008102224.txt us68752l1008102224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) ORTHOPEDIATRICS CORP - (Name of Issuer) Common Stock - (Title of Class of Securities) 68752L100 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| October 18, 2024 |
Employment Agreement This Employment Agreement (“Agreement”) is made and entered into this October 15, 2024, by and between Greg Odle (Employee”) and OrthoPediatrics Corp. |
|
| October 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2024 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| October 18, 2024 |
Employment Agreement This Employment Agreement (“Agreement”) is made and entered into this October 15, 2024, by and between Joseph (Joe) Hauser (Employee”) and OrthoPediatrics Corp. |
|
| October 18, 2024 |
Employment Agreement This Employment Agreement (“Agreement”) is made and entered into this October 15, 2024, by and between Daniel (Dan) Gerritzen (Employee”) and OrthoPediatrics Corp. |
|
| October 18, 2024 |
Employment Agreement This Employment Agreement (“Agreement”) is made and entered into this October 15, 2024, by and between Fred Hite (Employee”) and OrthoPediatrics Corp. |
|
| October 18, 2024 |
Employment Agreement This Employment Agreement (“Agreement”) is made and entered into this October 15, 2024, by and between David Bailey (Employee”) and OrthoPediatrics Corp. |
|
| September 12, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commissio |
|
| September 12, 2024 |
Investor Day September 12, 2024 www.OrthoPediatrics.com > 1,000,000 Kids Helped 22024 // Analyst Day Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations a |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission F |
|
| August 12, 2024 |
Form of 4.75% Convertible Senior Notes due February 15, 2030 Exhibit 4.2 FORM OF NOTE [Insert Global Note Legend, if applicable] [Insert Restricted Note Legend, if applicable] [Insert Non-Affiliate Legend] OrthoPediatrics Corp. 4.75% Convertible Senior Note due 2030 CUSIP No.: [][Insert for a “restricted” CUSIP number: *] Certificate No. [] ISIN No.: [][Insert for a “restricted” ISIN number: *] OrthoPediatrics Corp., a Delaware corporation, for value receiv |
|
| August 12, 2024 |
Exhibit 4.1 OrthoPediatrics Corp. and U.S. BANK Trust Company, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of August 12, 2024 4.75% Convertible Senior Notes due 2030 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 12 Section 1.03. Rules of Construction 13 Article 2. The Notes 14 Section 2.01. Form, Dating and |
|
| August 9, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fi |
|
| August 9, 2024 |
2024 Investor Presentation www.OrthoPediatrics.com 22 0 2 4 / / Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and conditio |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38242 OrthoPedia |
|
| August 5, 2024 |
Exhibit 10.2 PURCHASE AGREEMENT Braidwell Transaction Holdings LLC – Series 10 ( the “Purchaser”) is entering into this Purchase Agreement (the “Agreement”) with OrthoPediatrics Corp., a Delaware corporation (the “Company”), on August 5, 2024, whereby the Purchaser will purchase (the “Purchase”) the Company’s 4.75% Convertible Senior Notes due 2030 (the “Notes”) that will be issued pursuant |
|
| August 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fi |
|
| August 5, 2024 |
OrthoPediatrics Corp. Reports Second Quarter 2024 Financial Results and Reaffirms Full Year 2024 Revenue Guidance Record Second Quarter 2024 Revenue Increased 33% Year-over-Year WARSAW, Ind., August 5, 2024 - OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results |
|
| August 5, 2024 |
Exhibit 10.1 Execution Version CREDIT AGREEMENT AND GUARANTY dated as of August 5, 2024 by and among ORTHOPEDIATRICS CORP., ORTHOPEDIATRICS US DISTRIBUTION CORP., VILEX IN TENNESSEE, INC., ORTHEX, LLC, TELOS PARTNERS, LLC, MD ORTHOPAEDICS, INC., MD INTERNATIONAL, Inc. ORTHOPEDIATRICS US L.P., ORTHOPEDIATRICS IOWA HOLDCO, INC., ORTHOPEDIATRICS GP LLC, MEDTECH CONCEPTS LLC, boston brace internationa |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fi |
|
| August 5, 2024 |
Exhibit 99.1 OrthoPediatrics Corp. Announces Private Financing Term Loan and Private Placement of Convertible Notes Will Provide Up To $100 Million of Capital WARSAW, Indiana, August 5, 2024 — OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it has signed a private financing arrangement with Bra |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission File |
|
| May 28, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) ORTHOPEDIATRICS CORP. |
|
| May 28, 2024 |
OrthoPediatrics Corp. 2024 Incentive Award Plan Exhibit 10.1 ORTHOPEDIATRICS CORP. 2024 INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE The purpose of the OrthoPediatrics Corp. 2024 Incentive Award Plan (as it may be amended or restated from time to time, the “Plan”) is to promote the success and enhance the value of OrthoPediatrics Corp., a Delaware corporation (the “Company”), by linking the individual interests of the members of the Board, Employees |
|
| May 28, 2024 |
Form of OrthoPediatrics Corp. Restricted Stock Award Agreement Exhibit 10.2 ORTHOPEDIATRICS CORP. 2024 INCENTIVE AWARD PLAN RESTRICTED STOCK AWARD GRANT NOTICE OrthoPediatrics Corp., a Delaware corporation, (the “Company”), pursuant to the OrthoPediatrics Corp. 2024 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the individual listed below (the “Holder”), in consideration of the mutual agreements set forth herein and for oth |
|
| May 28, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission File |
|
| May 28, 2024 |
Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OrthoPediatrics Corp. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-1761833 (State or Other Jurisdiction of Incorporation or Organization) (IRS Employer Identification Number) 2850 Frontier Drive Warsaw, I |
|
| May 8, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission File |
|
| May 8, 2024 |
2024 Investor Presentation www.OrthoPediatrics.com 22 0 2 4 / / Disclaimer Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance a |
|
| May 8, 2024 |
KIDS / OrthoPediatrics Corp. / BlackRock Inc. Passive Investment SC 13G/A 1 us68752l1008050724.txt us68752l1008050724.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) ORTHOPEDIATRICS CORP - (Name of Issuer) Common Stock - (Title of Class of Securities) 68752L100 - (CUSIP Number) April 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38242 OrthoPedi |
|
| May 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission File |
|
| May 6, 2024 |
OrthoPediatrics Corp. Reports First Quarter 2024 Financial Results and Increases Full Year 2024 Revenue Guidance First Quarter 2024 Revenue Increased 41% Year-over-Year WARSAW, Ind., May 6, 2024 - OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the fir |
|
| April 17, 2024 |
OrthoPediatrics Corp. 2850 Frontier Drive Warsaw, Indiana 46582 April 17, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jessica Ansart Re: OrthoPediatrics Corp. Registration Statement on Form S-3 File No. 333-277996 Acceleration Request Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 22, 2024 |
United States securities and exchange commission logo March 22, 2024 David Bailey President and Chief Executive Officer OrthoPediatrics Corp. |
|
| March 15, 2024 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) ORTHOPEDIATRICS CORP. |
|
| March 15, 2024 |
As filed with the Securities and Exchange Commission on March 15, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 15, 2024 Registration No. |
|
| March 11, 2024 |
2024 Investor Presentation www.OrthoPediatrics.com 22 0 2 4 / / Disclaimer Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance a |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fi |
|
| March 8, 2024 |
DESCRIPTION OF ORTHOPEDIATRICS CORP. CAPITAL STOCK The following description summarizes some of the terms of our capital stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws, and the Delaware General Corporation Law, or the DGCL. Because it is only a summary, it does not contain all the information that may be important to you. For a |
|
| March 8, 2024 |
Subsidiaries of the registrant Subsidiaries of OrthoPediatrics Corp. As of December 31, 2023 Name of Subsidiary Jurisdiction of Formation Domestic Subsidiaries: OrthoPediatrics US Distribution Corp. Delaware Vilex in Tennessee, Inc. Tennessee Orthex, LLC Florida Telos Partners, LLC Colorado MD Orthopaedics, Inc. Iowa MD International, Inc. Iowa OrthoPediatrics GP LLC Delaware OrthoPediatrics US L.P. Delaware OrthoPediatrics Iow |
|
| March 8, 2024 |
LIMITED POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS that the undersigned directors and officers of OrthoPediatrics Corp. |
|
| March 8, 2024 |
OrthoPediatrics Clawback Policy ORTHOPEDIATRICS CORP. CLAWBACK POLICY (adopted effective November 1, 2023) 1.Purpose and Scope. OrthoPediatrics Corp. (the “Company”) has adopted this clawback policy (the “Policy”) to comply with Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (“Dodd-Frank”), as codified by Section 10D of the Securities Exchange Act of 1934 (the “Exchange Act”) and the rules o |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K [Mark One] ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38242 ORTHOPEDIATRICS CORP. |
|
| March 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fil |
|
| March 6, 2024 |
OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results Record full year 2023 revenue of $148.7 million increased 22% compared to prior year WARSAW, Ind., March 6, 2024 - OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its financial results for the fou |
|
| February 14, 2024 |
KIDS / OrthoPediatrics Corp. / BROWN CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 5)* OrthoPediatrics Corp. (Name of Issuer) Class A common stock, $0.00025 par value (Title of Class of Securities) 68752L100 (CUSIP Number) Eddie C. Brown Bro |
|
| February 9, 2024 |
KIDS / OrthoPediatrics Corp. / BROWN ADVISORY INC - BROWN ADVISORY INC Passive Investment SC 13G/A 1 kidsa320924.htm BROWN ADVISORY INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* OrthoPediatrics Corp. (Name of Issuer) (Title of Class of Securities) 68752L100 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 31, 2024 |
KIDS / OrthoPediatrics Corp. / BlackRock Inc. Passive Investment SC 13G 1 us68752l1008013124.txt us68752l1008013124.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) ORTHOPEDIATRICS CORP - (Name of Issuer) Common Stock - (Title of Class of Securities) 68752L100 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| January 8, 2024 |
Exhibit 2.1 Execution Version STOCK PURCHASE AGREEMENT BY AND AMONG ORTHOPEDIATRICS CORP., as purchaser, Boston brace international, Inc., as the Company, and GREATBANC TRUST COMPANY, SOLELY in ITS capacity as trustee of the boston brace international, Inc. Employee stock ownership trust, THE SELLING EQUITYHOLDERS (AS DEFINED HEREIN), AND Thomas Morrissey, SOLELY in HIS capacity as Sellers’ REPRES |
|
| January 8, 2024 |
Exhibit 99.1 OrthoPediatrics Corp. Announces Acquisition of Boston Orthotics & Prosthetics Combined organizations have helped more than 1 million kids Expands Specialty Bracing Division with pediatric orthotic management business offering leading technology and pediatric care through dedicated clinics Closes $80 million debt financing to support acquisition and future business requirements WARSAW, |
|
| January 8, 2024 |
OrthoPediatrics Corp. Announces Preliminary Unaudited Financial Highlights for the Fourth Quarter & Full Year 2023 Issues 2024 financial guidance WARSAW, Ind., January 8, 2024 - OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited net revenue for the fourth qua |
|
| January 8, 2024 |
2024 Investor Presentation www.OrthoPediatrics.com 22 0 2 4 / / Disclaimer Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance a |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission F |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission F |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| January 2, 2024 |
Exhibit 10.1 Execution Version CREDIT, SECURITY AND GUARANTY AGREEMENT dated as of December 29, 2023 by and among ORTHOPEDIATRICS CORP., ORTHOPEDIATRICS US DISTRIBUTION CORP., VILEX IN TENNESSEE, INC., ORTHEX, LLC, TELOS PARTNERS, LLC, MD ORTHOPAEDICS, INC., MD INTERNATIONAL, Inc. ORTHOPEDIATRICS US L.P., ORTHOPEDIATRICS IOWA HOLDCO, INC., ORTHOPEDIATRICS GP LLC, MEDTECH CONCEPTS LLC, each as Borr |
|
| November 13, 2023 |
2023 Investor Presentation www.OrthoPediatrics.com 22 0 2 3 / / Disclaimer Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance a |
|
| November 13, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| November 8, 2023 |
1 AMENDED AND RESTATED BYLAWS OF ORTHOPEDIATRICS CORP. (as of November 2, 2023) ARTICLE I: OFFICES Section 1.1 Registered Agent and Office. The registered office and registered agent of OrthoPediatrics Corp. (the “Corporation”) in the State of Delaware shall be as set forth in the Corporation’s certificate of incorporation (as may be amended and/or restated from time to time, the “Certificate of I |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| November 8, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission F |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38242 Ortho |
|
| November 6, 2023 |
OrthoPediatrics Corp. Reports Third Quarter 2023 Financial Results Record Setting Quarterly Revenue of $40.0 million WARSAW, Ind., November 6, 2023 - OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2023. Third Quar |
|
| November 6, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| August 7, 2023 |
2023 Investor Presentation www.OrthoPediatrics.com 22 0 2 3 / / Disclaimer Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance a |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fi |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38242 OrthoPedia |
|
| July 31, 2023 |
OrthoPediatrics Corp. Reports Second Quarter 2023 Financial Results Record Setting Quarterly Revenue of $39.6 million WARSAW, Ind., July 31, 2023 - OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the second quarter ended June 30, 2023. Second Quarter 2 |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fil |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fil |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission File |
|
| May 16, 2023 |
may-2023orthopediatricsx 2023 Investor Presentation www.OrthoPediatrics.com 22 0 2 3 / / Disclaimer Forward-Looking Statements All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations an |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38242 OrthoPedi |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission File |
|
| May 1, 2023 |
Exhibit 10.1 ORTHOPEDIATRICS CORP. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Effective as of January1, 2023) OrthoPediatrics Corp. (the “Company”) believes that granting equity and cash compensation to its directors who are not employees of the Company (“Outside Directors”) represents a powerful tool to attract, retain and reward its Outside Directors and to align the interests of its Outside Dir |
|
| May 1, 2023 |
OrthoPediatrics Corp. Reports First Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance First Quarter 2023 Revenue Increased 35% Year-over-Year WARSAW, Ind., May 1, 2023 - OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the fir |
|
| May 1, 2023 |
Exhibit 2.1 MEMBERSHIP INTEREST PURCHASE AGREEMENT BY AND AMONG ORTHOPEDIATRICS CORP., as purchaser, AND KEVIN UNGER AND DINZE LLC, AS SELLERS, DATED AS OF MAY 1, 2023 LIST OF EXHIBITS AND SCHEDULES Exhibits to Membership Interest Purchase Agreement Exhibit A – Stock Power Exhibit B – Membership Interest Assignment Agreement Exhibit C – Sellers’ Release Exhibit D – Form of Resignation Exhibit E – |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fi |
|
| April 28, 2023 |
DEFA14A 1 opproxyadditionalproxysoli.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commissio |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fil |
|
| March 8, 2023 |
march-2023orthopediatric 2023 Investor Presentation www.OrthoPediatrics.com 22 0 2 3 / / Disclaimer Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of U.S. federal securities laws. You can identify forward-looking statements by the use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "believe," "estima |
|
| March 1, 2023 |
Execution Version FIFTH AMENDMENT TO FOURTH AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This FIFTH AMENDMENT TO FOURTH AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of November 15, 2022, by and among Squadron Capital LLC, a Delaware limited liability company (“Lender”), OrthoPediatrics Corp. |
|
| March 1, 2023 |
LIMITED POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS that the undersigned directors and officers of OrthoPediatrics Corp. |
|
| March 1, 2023 |
DESCRIPTION OF ORTHOPEDIATRICS CORP. CAPITAL STOCK The following description summarizes some of the terms of our capital stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws, and the Delaware General Corporation Law, or the DGCL. Because it is only a summary, it does not contain all the information that may be important to you. For a |
|
| March 1, 2023 |
Subsidiaries of the registrant Subsidiaries of OrthoPediatrics Corp. As of December 31, 2022 Name of Subsidiary Jurisdiction of Formation Domestic Subsidiaries: OrthoPediatrics US Distribution Corp. Delaware Vilex in Tennessee, Inc. Tennessee Orthex, LLC Florida Telos Partners, LLC Colorado MD Orthopaedics, Inc. Iowa MD International Iowa OrthoPediatrics GP LLC Delaware OrthoPediatrics US L.P. Delaware OrthoPediatrics Iowa Hold |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K [Mark One] ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38242 ORTHOPEDIATRICS CORP. |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| February 28, 2023 |
OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2022 Financial Results Fourth Quarter 2022 Revenue Increased 25% Year-over-Year Full Year 2022 Revenue Increased 25% Year-over-Year WARSAW, Ind., February 28, 2023 - OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its f |
|
| February 14, 2023 |
KIDS / Orthopediatrics Corp / BROWN CAPITAL MANAGEMENT LLC Passive Investment SC 13G/A 1 fp0081795-1sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 4)* OrthoPediatrics Corp. (Name of Issuer) Class A common stock, $0.00025 par value (Title of Class of Securities) 68752L100 |
|
| February 9, 2023 |
KIDS / Orthopediatrics Corp / BROWN ADVISORY INC - BROWN ADVISORY INCORPORATED Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* OrthoPediatrics Corp. (Name of Issuer) (Title of Class of Securities) 68752L100 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| February 8, 2023 |
KIDS / Orthopediatrics Corp / RIVERBRIDGE PARTNERS LLC - ORTHOPEDIATRICS CORP Passive Investment SC 13G/A 1 g13kidsamend2.txt ORTHOPEDIATRICS CORP Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) OrthoPediatrics Corp (Name of Issuer) COMMON STOCK (Title of Class of Securities) 68752L100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Rule 13d-1(b) *The remainder of this cov |
|
| January 9, 2023 |
OrthoPediatrics Corp. Announces Preliminary Unaudited Net Revenue for the Fourth Quarter & Full Year 2022, Provides Financial Outlook for 2023 WARSAW, Ind., January 9, 2023 - OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited net revenue for the fourth quarte |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission F |
|
| January 9, 2023 |
2023 Investor Presentation www.OrthoPediatrics.com 22 0 2 2 / / Disclaimer Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of U.S. federal securities laws. You can identify forward-looking statements by the use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "believe," "estimate," "project," "target," |
|
| November 1, 2022 |
2022 Investor Presentation www.OrthoPediatrics.com 22 0 2 2 / / Disclaimer Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of U.S. federal securities laws. You can identify forward-looking statements by the use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "believe," "estimate," "project," "target," |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38242 Ortho |
|
| November 1, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| October 31, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| October 31, 2022 |
OrthoPediatrics Corp. Reports Third Quarter 2022 Financial Results and Updates 2022 Revenue Guidance Third Quarter 2022 Record Revenue Increased 39% Year-over-Year WARSAW, Ind., October 31, 2022 - OrthoPediatrics Corp. (?OrthoPediatrics? or the ?Company?) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its financial results for the thi |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| October 20, 2022 |
OrthoPediatrics Corp. Announces Appointment of Jimmy D. McDonald to Board of Directors WARSAW, Indiana, October 20, 2022 ? OrthoPediatrics Corp. (?OrthoPediatrics? or the ?Company?) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the appointment of Jimmy D. McDonald to its board of directors, effective October 18, 2022. Mark Throdahl, |
|
| September 22, 2022 |
KIDS / Orthopediatrics Corp / Squadron Capital LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 204. |
|
| August 17, 2022 |
Exhibit 99.6 Excution Copy Lock-Up Agreement August 9, 2022 Stifel, Nicolaus & Company, Incorporated As representative of the underwriters named in Schedule II to the Underwriting Agreement referred to below c/o Stifel, Nicolaus & Company, Incorporated 787 7th Avenue, 11th Floor New York, NY 10019 Ladies and Gentlemen: As an inducement to the underwriters (the ?Underwriters?) to execute an underwr |
|
| August 17, 2022 |
KIDS / Orthopediatrics Corp / Squadron Capital LLC - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 204. |
|
| August 12, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission F |
|
| August 12, 2022 |
TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5)? ?Registration Statement No. 333-237177? PROSPECTUS SUPPLEMENT (To Prospectus dated March 27, 2020) ORTHOPEDIATRICS CORP. 750,000 Shares of Common Stock Pre-Funded Warrants to Purchase 1,525,000 Shares of Common Stock We are offering 750,000 shares of our common stock and, in lieu of common stock, pre-funded warrants to purchase 1,525,000 shares |
|
| August 12, 2022 |
Exhibit?1.1 ? Execution ? 2,275,000 Shares ? OrthoPediatrics Corp. ? Common Stock ? UNDERWRITING AGREEMENT ? August?10, 2022 ? PIPER SANDLER?& CO. Stifel, Nicolaus?& Company,?Incorporated ?????As Representatives of the several ?????Underwriters named in Schedule?I hereto ? c/o Piper Sandler?& Co. 800 Nicollet Mall Minneapolis, Minnesota 55402 ? c/o Stifel, Nicolaus?& Company,?Incorporated 787 7th |
|
| August 12, 2022 |
Form of Pre-Funded Common Stock Purchase Warrant. Exhibit 4.1 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT ORTHOPEDIATRICS CORP. Warrant Shares: [?] Date of Issuance: [?], 2022 (such date, the ?Issue Date?) Warrant No.: [?] THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, the registered holder hereof or its permitted assigns (the ?Holder?) is entitled, upon the terms and subject to the limitati |
|
| August 12, 2022 |
OrthoPediatrics Corp. (Exact Name of Registrant as Specified in its Charter) EX-FILING FEES 2 tm2222906d5ex-filingfees.htm EX-FILING FEES Exhibit 107 OrthoPediatrics Corp. (Exact Name of Registrant as Specified in its Charter) The prospectus to which this Exhibit 107 is attached is a final prospectus for the related offering. The maximum aggregate offering price for such offering is $143,893,750. |
|
| August 12, 2022 |
OrthoPediatrics Corp. Announces Proposed Offering of Common Stock and Pre-Funded Warrants Exhibit 99.1 OrthoPediatrics Corp. Announces Proposed Offering of Common Stock and Pre-Funded Warrants WARSAW, Indiana, August 10, 2022 ? OrthoPediatrics Corp. (?OrthoPediatrics? or the ?Company?) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it has commenced an underwritten public offering of its common stock and, in lieu of common |
|
| August 12, 2022 |
Exhibit 99.2 OrthoPediatrics Corp. Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants WARSAW, Indiana, August 11, 2022 ? OrthoPediatrics Corp. (?OrthoPediatrics? or the ?Company?) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the pricing of its previously announced underwritten public offering o |
|
| August 10, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) OrthoPediatrics Corp. |
|
| August 10, 2022 |
Subject to completion, dated August 10, 2022 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| August 10, 2022 |
As filed with the Securities and Exchange Commission on August 10, 2022 As filed with the Securities and Exchange Commission on August 10, 2022 Registration No. |
|
| August 4, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fi |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38242 OrthoPedia |
|
| August 4, 2022 |
2022 Investor Presentation www.OrthoPediatrics.com 22 0 2 2 / / Disclaimer Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of U.S. federal securities laws. You can identify forward-looking statements by the use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "believe," "estimate," "project," "target," |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fi |
|
| August 3, 2022 |
OrthoPediatrics Corp. Reports Second Quarter 2022 Financial Results and Increases 2022 Revenue Guidance Second Quarter 2022 Record Revenue Increased 23% Year-over-Year Second Quarter 2022 Record Adjusted EBITDA of $2.1 million WARSAW, Ind., August 3, 2022 - OrthoPediatrics Corp. (?OrthoPediatrics? or the ?Company?) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric o |
|
| June 15, 2022 |
Exhibit 10.2 SECOND AMENDED AND RESTATED REVOLVING NOTE $50,000,000 June 13, 2022 FOR VALUE RECEIVED, the undersigned, OrthoPediatrics Corp., a Delaware corporation (?OrthoPediatrics?), OrthoPediatrics US Distribution Corp., a Delaware corporation (?OrthoPediatrics US?), OrthoPediatrics EU Limited, a company incorporated and registered in England and Wales (?OrthoPediatrics EU?), OrthoPediatrics A |
|
| June 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fil |
|
| June 15, 2022 |
Exhibit 10.1 Execution Version FOURTH AMENDMENT TO FOURTH AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This FOURTH AMENDMENT TO FOURTH AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this ?Amendment?) is entered into as of June 13, 2022, by and among Squadron Capital LLC, a Delaware limited liability company (?Lender?), OrthoPediatrics Corp., a Delaware corporation (?OrthoPediatrics?) and th |
|
| June 14, 2022 |
Exhibit 99.1 OrthoPediatrics Corp. Announces Deal to Acquire Pega Medical Expands portfolio of trauma and deformity systems for pediatric orthopedics, including the Fassier-Duval Telescopic IM System? WARSAW, Indiana, June 14, 2022 ? OrthoPediatrics Corp. (?OrthoPediatrics? or the ?Company?) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced th |
|
| June 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fil |
|
| June 14, 2022 |
Exhibit 2.1 Ariel Dujovne, Fiducie Pega, 1411179 Canada Inc., Enrique Garcia-Belenguer, Fiducie Familiale EGB, Fady Rayes, Fiducie Fady Rayes, and James Edward Orsak as Vendors and ORTHOPEDIATRICS CANADA ULC as Purchaser and OrthoPediatrics Corp. as Solidary Co-Debtor SALE AND PURCHASE AGREEMENT June 13, 2022 TABLE OF CONTENTS Article 1 INTERPRETATION 2 1.1 Defined Terms 2 1.2 Gender and Number 14 |
|
| June 1, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission File |
|
| May 10, 2022 |
2022 Investor Presentation www.OrthoPediatrics.com 22 0 2 2 / / Disclaimer Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of U.S. federal securities laws. You can identify forward-looking statements by the use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "believe," "estimate," "project," "target," |
|
| May 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission File |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38242 OrthoPedi |
|
| May 5, 2022 |
Employment Agreement, by and between the registrant and Joseph W. Hauser, dated as of March Employment Agreement This Employment Agreement (“Agreement”) is made and entered into this 1st day of March, 2022, by and between Joe Hauser (“Employee”) and OrthoPediatrics Corp. |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission File |
|
| May 4, 2022 |
OrthoPediatrics Corp. Reports First Quarter 2022 Financial Results and Increases 2022 Revenue Guidance First Quarter 2022 Revenue Increased 9% Year-over-Year WARSAW, Ind., May 4, 2022 - OrthoPediatrics Corp. (?OrthoPediatrics? or the ?Company?) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its financial results for the first quarter |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 4, 2022 |
Exhibit 10.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG ORTHOPEDIATRICS CORP., as PARENT, ORTHOPEDIATRICS IOWA HOLDCO, INC., AS MERGER SUB, MITCHELL DESIGNS, INC., AS TARGET COMPANY, AND JOHN MITCHELL, as shareholder DATED AS OF APRIL 1, 2022 AGREEMENT AND PLAN OF MERGER This AGREEMENT AND PLAN OF MERGER (this ?Agreement?) is made and entered into as of April 1, 2022, by and among (i) OrthoPediatri |
|
| April 4, 2022 |
EX-99.1 3 tm2211219d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 OrthoPediatrics Corp. Announces Acquisition of MD Orthopaedics Expands portfolio with a patented, non-operative solution for the treatment of clubfoot WARSAW, Indiana, April 4, 2022 — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, anno |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2022 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fil |
|
| March 4, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2022 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fil |
|
| March 4, 2022 |
EX-99.1 2 mar422orthopediatrics-in.htm EX-99.1 2022 Investor Presentation www.OrthoPediatrics.com 22 0 2 2 / / Disclaimer Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of U.S. federal securities laws. You can identify forward-looking statements by the use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "coul |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K [Mark One] ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38242 ORTHOPEDIATRICS CORP. |
|
| March 3, 2022 |
DESCRIPTION OF ORTHOPEDIATRICS CORP. CAPITAL STOCK The following description summarizes some of the terms of our capital stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws, and the Delaware General Corporation Law, or the DGCL. Because it is only a summary, it does not contain all the information that may be important to you. For a |
|
| March 3, 2022 |
Subsidiaries of the registrant Subsidiaries of OrthoPediatrics Corp. As of December 31, 2021 Name of Subsidiary Jurisdiction of Formation Domestic Subsidiaries: OrthoPediatrics US Distribution Corp. Delaware Vilex in Tennessee, Inc. Tennessee Orthex, LLC Florida Telos Partners, LLC Colorado International Subsidiaries: OrthoPediatrics EU Limited United Kingdom OrthoPediatrics AUS PTY LTD Australia OrthoPediatrics NZ Limited New |
|
| March 3, 2022 |
LIMITED POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS that the undersigned directors and officers of OrthoPediatrics Corp. |
|
| March 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2022 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission Fil |
|
| March 2, 2022 |
OrthoPediatrics Corp. Reports Fourth Quarter and Record Full Year 2021 Financial Results Fourth Quarter 2021 Revenue Increased 31% Year-over-Year 2021 Revenue Increased 38% Year-over-Year WARSAW, Ind., March 2, 2022 - OrthoPediatrics Corp. (?OrthoPediatrics? or the ?Company?) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its financia |
|
| February 24, 2022 |
KIDS / Orthopediatrics Corp / BlackRock Inc. Passive Investment us68752l1008022422.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) ORTHOPEDIATRICS CORP - (Name of Issuer) Common Stock - (Title of Class of Securities) 68752L100 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 14, 2022 |
KIDS / Orthopediatrics Corp / BROWN CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 3)* OrthoPediatrics Corp. (Name of Issuer) Class A common stock, $0.00025 par value (Title of Class of Securities) 68752L100 (CUSIP Number) Eddie C. Brown Bro |
|
| February 7, 2022 |
KIDS / Orthopediatrics Corp / BROWN ADVISORY INC - BROWN ADVISORY INCORPORATED Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* OrthoPediatrics Corp. (Name of Issuer) (Title of Class of Securities) 68752L100 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| January 21, 2022 |
Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 10, 2022 |
OrthoPediatrics Announces Preliminary Unaudited Revenue for the Fourth Quarter & Full-Year 2021 EX-99.1 2 kidsq4fullyear2021prelimin.htm EX-99.1 OrthoPediatrics Announces Preliminary Unaudited Revenue for the Fourth Quarter & Full-Year 2021 WARSAW, Indiana, January 10, 2022— OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited revenue for the fourth quart |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| January 10, 2022 |
2022 Investor Presentation www.OrthoPediatrics.com 22 0 2 2 / / Disclaimer Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of U.S. federal securities laws. You can identify forward-looking statements by the use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "believe," "estimate," "project," "target," |
|
| January 6, 2022 |
Execution Version THIRD AMENDMENT TO FOURTH AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This THIRD AMENDMENT TO FOURTH AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this ?Amendment?) is entered into on January 4, 2022 but made effective as of December 31, 2021, by and among Squadron Capital LLC, a Delaware limited liability company (?Lender?), OrthoPediatrics Corp. |
|
| January 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2022 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission F |
|
| November 8, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| November 8, 2021 |
2021 Investor Presentation www.OrthoPediatrics.com 22 0 2 1 / / Disclaimer Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of U.S. federal securities laws. You can identify forward-looking statements by the use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "believe," "estimate," "project," "target," |
|
| November 4, 2021 |
OrthoPediatrics Corp. Non-Employee Director Compensation Policy, effective January 1, 2022 21654636.v1 ORTHOPEDIATRICS CORP. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Effective as of January 1, 2022) OrthoPediatrics Corp. (the ?Company?) believes that granting equity and cash compensation to its directors who are not employees of the Company (?Outside Directors?) represents a powerful tool to attract, retain and reward its Outside Directors and to align the interests of its Outside Dir |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38242 Ortho |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| November 3, 2021 |
OrthoPediatrics Corp. Reports Third Quarter 2021 Financial Results Third Quarter 2021 Revenue Increased 13% Year-over-Year WARSAW, Ind., November 3, 2021 - OrthoPediatrics Corp. (?OrthoPediatrics? or the ?Company?) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its financial results for the third quarter ended September 30, 2021. Thir |
|
| October 13, 2021 |
OrthoPediatrics Corp. Announces Preliminary Unaudited Revenue for the Third Quarter 2021 and Reiterates 2021 Revenue Guidance WARSAW, Indiana, October 13, 2021? OrthoPediatrics Corp. (?OrthoPediatrics? or the ?Company?) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary revenue for the third quarter ended September 30, 2021 an |
|
| October 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2021 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission |
|
| August 12, 2021 |
EX-99.1 2 kidsaugust2021investorpr.htm EX-99.1 David Bailey, President & CEO Fred Hite, COO & CFO Mark Throdahl, Executive Chairman OrthoPediatrics Corp. August 2021 Disclaimer Forward‐Looking Statements This presentation includes "forward‐looking statements" within the meaning of U.S. federal securities laws. You can identify forward‐looking statements by the use of words such as "may," "might," |
|
| August 12, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38242 26-1761833 (Commission F |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38242 OrthoPedia |
|
| August 5, 2021 |
OrthoPediatrics Corp. Non-Employee Director Compensation Policy EX-10.5 2 kidsnon-employeedirectorco.htm EX-10.5 ORTHOPEDIATRICS CORP. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Effective as of August 1, 2021) OrthoPediatrics Corp. (the “Company”) believes that granting equity and cash compensation to its directors who are not employees of the Company (“Outside Directors”) represents a powerful tool to attract, retain and reward its Outside Directors and to al |
|
| August 4, 2021 |
EX-99.1 2 kidsq22021earningsrelease.htm EX-99.1 OrthoPediatrics Corp. Reports Second Quarter 2021 Financial Results Second Quarter 2021 Revenue Increased 96% Year-over-Year with Continued Strong Domestic Growth WARSAW, Ind., Aug. 4, 2021 - OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announ |
